Endocyte Inc. (ECYT)

17.06 0 (0%)

IEX Real-Time Price

August 16, 2018 EST.

Nasdaq Global Select : Healthcare

Prev Close 17.06

Price Open 16.5

Volume: 777,664

Avg Volume: 810,094

Market Cap: 1.19B

P/E Ratio -21.06

52 Wk Range 1.17-17.7



ECYT Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-07-31
67.74M
7.47M
7.44
11.03%

2018-07-13
67.23M
7.32M
4.46
10.89%

2018-06-29
67.23M
8.05M
4.83
11.97%

2018-06-15
67.23M
3.57M
2.51
5.30%




ECYT Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-07-31
Q2 2018
N/A
-0.19 (3)
-0.17
0.02

2018-05-09
Q1 2018
N/A
-0.18 (3)
-0.16
0.03

2018-03-09
Q4 2017
N/A
-0.16 (2)
-0.16
0.03

2018-02-26
Q4 2017
BTO
-0.16 (2)
-0.16
0.03

News

Endocyte, Inc. (ECYT) CEO Mike Sherman on Q2 2018 Results - Earnings Call Transcript (2018-07-31 11:42 SeekingAlpha)

Endocyte, Inc. (ECYT) Q2 2018 Results Earnings Conference Call July 31, 2018 08:30 AM ET Executives Mike Sherman - President and CEO Dr. Alison Armour - Chief Medical Officer Michael Andriole - CFO Analysts Boris Peaker - Cowen David Nierengarten - Wedbush Securities Ma…

 

Endocyte Is A Solid Buy Opportunity For 2018 (2018-07-31 11:21 SeekingAlpha)

Endocyte ( ECYT ) is a development-stage biopharmaceutical company, mainly focused on developing small-molecule drug conjugates or SMDC and companion imaging agents for treating various oncology and inflammatory conditions. A big turning point for the company has been acquisition of global r…

 

Endocyte Q2 revenues up 8%; shares up 3% premarket (2018-07-31 08:46 SeekingAlpha)

Endocyte ( ECYT ) Q2 results : Revenues: $14K (+7.7%); Net Loss: ($11.6M) (+0.9%); Loss Per Share: ($0.17) (+39.3%). More news on: Endocyte, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more …

 

Endocyte EPS and revenue in-line (2018-07-31 08:02 SeekingAlpha)

Endocyte (NASDAQ: ECYT ): Q2 EPS of -$0.17 in-line. More news on: Endocyte, Inc., Earnings news and commentary, Healthcare stocks news, Read more …

 


Statistics

Shares Outstanding: 70.01M

Top 15 Institution Percent: 78.60

Price To Sales: 15425.99

Price To Book: 6.96

Revenue: 32500

Gross Profit: N/A

Cash: 103.08M

Debt: N/A

Return On Assets: -35.36

Return On Equity: -36.90

Profit Margin: N/A

Price History

Beta: 0.13

50-day Moving Avg: 15.40

200-day Moving Avg: 9.08

YTD Change: N/A

5-day Change: 7.09

1-month Change: 3.39

3-month Change: 35.83

6-month Change: N/A

1-year Change: N/A

Revenue Per Share: 0.00

Revenue Per Employee: 739.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Endocyte Inc.

Exchange: Nasdaq Global Select

Industry: Biotechnology

Sector: Healthcare

Website: http://www.endocyte.com

Endocyte Inc is a biopharmaceutical company. It is engaged in developing targeted therapies for the treatment of cancer and inflammatory diseases.